Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1993 Aug;109(4):1046–1052. doi: 10.1111/j.1476-5381.1993.tb13727.x

The effects of alpha 2-adrenoceptor antagonists on the inhibition of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head shakes by 5-HT1A receptor agonists in the mouse.

S M Dursun 1, S L Handley 1
PMCID: PMC2175745  PMID: 8104640

Abstract

1. 8-Hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT), gepirone, buspirone and ipsapirone dose-dependently antagonized the head-shakes induced by 1-(2,5-dimethoxy 4-iodophenyl)-2-amino propane hydrochloride (DOI) (1.0 mg kg-1) in mice, when these agents were given i.p. 10 min beforehand. 2. para-Chlorophenylalanine (pCPA) abolished the effect of 8-OH-DPAT (0.1 mg kg-1) and of buspirone (1.0 mg kg-1). (+/-)-Pindolol (5.0 mg kg-1) also antagonized the effect of 8-OH-DPAT (0.1 mg kg-1). 3. The alpha 2-adrenoceptor antagonists, RX811059 (1.0 mg kg-1), idazoxan (0.5 mg kg-1), yohimbine (1.0 mg kg-1) and 1-(2-pyrimidinyl)-piperazine (1-PP) (2.0 mg kg-1) i.p. prevented the antagonistic effect of 8-OH-DPAT (0.1 mg kg-1) on DOI-head-shakes. 4. Orally-administered buspirone, given 60 min beforehand, only reduced DOI-head-shakes at doses of 60 mg kg-1 and above. However, when buspirone (1.0 mg kg-1) was administered orally twice daily for 21 days, DOI-head-shakes were significantly reduced when tested 60 min after the first daily dose on days 5, 12 and 21 and 48 h after withdrawal. 5. A single oral dose of buspirone (1.0 mg kg-1) strongly antagonized DOI-head-shakes when given 24 h after the last of 4 daily doses of 1-PP (2.0 mg kg-1, p.o.) but had no effect on DOI-head-shakes 24 h after the last of 4 daily doses of water (p.o.).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1046

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnt J., Hyttel J. Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol. 1989 Feb 14;161(1):45–51. doi: 10.1016/0014-2999(89)90178-7. [DOI] [PubMed] [Google Scholar]
  2. Backus L. I., Sharp T., Grahame-Smith D. G. Behavioural evidence for a functional interaction between central 5-HT2 and 5-HT1A receptors. Br J Pharmacol. 1990 Aug;100(4):793–799. doi: 10.1111/j.1476-5381.1990.tb14094.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Baraban J. M., Aghajanian G. K. Noradrenergic innervation of serotonergic neurons in the dorsal raphe: demonstration by electron microscopic autoradiography. Brain Res. 1981 Jan 5;204(1):1–11. doi: 10.1016/0006-8993(81)90646-6. [DOI] [PubMed] [Google Scholar]
  4. Bednarczyk B., Vetulani J. Antagonism of clonidine to shaking behavior in morphine abstinence syndrome and to head twitches produced by serotonergic agents in the rat. Pol J Pharmacol Pharm. 1978 Mar-Jun;30(2-3):307–322. [PubMed] [Google Scholar]
  5. Berendsen H. H., Broekkamp C. L. Behavioural evidence for functional interactions between 5-HT-receptor subtypes in rats and mice. Br J Pharmacol. 1990 Nov;101(3):667–673. doi: 10.1111/j.1476-5381.1990.tb14138.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bianchi G., Caccia S., Della Vedova F., Garattini S. The alpha 2-adrenoceptor antagonist activity of ipsapirone and gepirone is mediated by their common metabolite 1-(2-pyrimidinyl)-piperazine (PmP). Eur J Pharmacol. 1988 Jul 14;151(3):365–371. doi: 10.1016/0014-2999(88)90532-8. [DOI] [PubMed] [Google Scholar]
  7. Bianchi G., Garattini S. Blockade of alpha 2-adrenoceptors by 1-(2-pyrimidinyl)-piperazine (PmP) in vivo and its relation to the activity of buspirone. Eur J Pharmacol. 1988 Mar 15;147(3):343–350. doi: 10.1016/0014-2999(88)90167-7. [DOI] [PubMed] [Google Scholar]
  8. Blier P., de Montigny C. Modification of 5-HT neuron properties by sustained administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain. Synapse. 1987;1(5):470–480. doi: 10.1002/syn.890010511. [DOI] [PubMed] [Google Scholar]
  9. Boulton C. S., Handley S. L. Factors modifying the head-twitch response to 5-hydroxytryptophan. Psychopharmacologia. 1973 Jul 19;31(3):205–214. doi: 10.1007/BF00422511. [DOI] [PubMed] [Google Scholar]
  10. Bristow L. J., Baucutt L., Thorn L., Hutson P. H., Noble A., Beer M., Middlemiss D. N., Tricklebank M. D. Behavioural and biochemical evidence of the interaction of the putative antipsychotic agent, BMY 14802 with the 5-HT1A receptor. Eur J Pharmacol. 1991 Oct 29;204(1):21–28. doi: 10.1016/0014-2999(91)90830-j. [DOI] [PubMed] [Google Scholar]
  11. Caccia S., Conti I., Viganò G., Garattini S. 1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986;33(1):46–51. doi: 10.1159/000138199. [DOI] [PubMed] [Google Scholar]
  12. Caccia S., Fossati T., Mancinelli A. Disposition and metabolism of minaprine in the rat. Xenobiotica. 1985 Dec;15(12):1111–1119. doi: 10.3109/00498258509049105. [DOI] [PubMed] [Google Scholar]
  13. Darmani N. A., Martin B. R., Pandey U., Glennon R. A. Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions. Pharmacol Biochem Behav. 1990 Sep;37(1):95–99. doi: 10.1016/0091-3057(90)90047-l. [DOI] [PubMed] [Google Scholar]
  14. FUXE K. EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. IV. DISTRIBUTION OF MONOAMINE NERVE TERMINALS IN THE CENTRAL NERVOUS SYSTEM. Acta Physiol Scand Suppl. 1965:SUPPL 247–247:37+. [PubMed] [Google Scholar]
  15. Fozard J. R., Mir A. K., Middlemiss D. N. Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol. 1987 Mar;9(3):328–347. doi: 10.1097/00005344-198703000-00010. [DOI] [PubMed] [Google Scholar]
  16. Garratt J. C., Crespi F., Mason R., Marsden C. A. Effects of idazoxan on dorsal raphe 5-hydroxytryptamine neuronal function. Eur J Pharmacol. 1991 Jan 25;193(1):87–93. doi: 10.1016/0014-2999(91)90204-4. [DOI] [PubMed] [Google Scholar]
  17. Glennon R. A. Central serotonin receptors as targets for drug research. J Med Chem. 1987 Jan;30(1):1–12. doi: 10.1021/jm00384a001. [DOI] [PubMed] [Google Scholar]
  18. Godbout R., Chaput Y., Blier P., de Montigny C. Tandospirone and its metabolite, 1-(2-pyrimidinyl)-piperazine--I. Effects of acute and long-term administration of tandospirone on serotonin neurotransmission. Neuropharmacology. 1991 Jul;30(7):679–690. doi: 10.1016/0028-3908(91)90175-b. [DOI] [PubMed] [Google Scholar]
  19. Goldberg H. L., Finnerty R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry. 1979 Sep;136(9):1184–1187. doi: 10.1176/ajp.136.9.1184. [DOI] [PubMed] [Google Scholar]
  20. Goodwin G. M., De Souza R. J., Green A. R. The effects of a 5-HT1 receptor ligand isapirone (TVX Q 7821) on 5-HT synthesis and the behavioural effects of 5-HT agonists in mice and rats. Psychopharmacology (Berl) 1986;89(3):382–387. doi: 10.1007/BF00174379. [DOI] [PubMed] [Google Scholar]
  21. Goodwin G. M., Green A. R. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol. 1985 Mar;84(3):743–753. doi: 10.1111/j.1476-5381.1985.tb16157.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gorea E., Davenne D., Lanfumey L., Chastanet M., Adrien J. Regulation of noradrenergic coerulean neuronal firing mediated by 5-HT2 receptors: involvement of the prepositus hypoglossal nucleus. Neuropharmacology. 1991 Dec;30(12A):1309–1318. doi: 10.1016/0028-3908(91)90028-a. [DOI] [PubMed] [Google Scholar]
  23. Gow I. F., Corrie J. E., Williams B. C., Edwards C. R. Development and validation of an improved radioimmunoassay for serotonin in platelet-rich plasma. Clin Chim Acta. 1987 Jan 30;162(2):175–188. doi: 10.1016/0009-8981(87)90449-9. [DOI] [PubMed] [Google Scholar]
  24. Göthert M., Huth H. Alpha-adrenoceptor-mediated modulation of 5-hydroxytryptamine release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1980 Aug;313(1):21–26. doi: 10.1007/BF00505800. [DOI] [PubMed] [Google Scholar]
  25. Göthert M., Huth H., Schlicker E. Characterization of the receptor subtype involved in alpha-adrenoceptor-mediated modulation of serotonin release from rat brain cortex slices. Naunyn Schmiedebergs Arch Pharmacol. 1981 Nov;317(3):199–203. doi: 10.1007/BF00503816. [DOI] [PubMed] [Google Scholar]
  26. Handley S. L., Brown J. Effects on the 5-hydroxytryptamine-induced head-twitch of drugs with selective actions on alpha1 and alpha2-adrenoceptors. Neuropharmacology. 1982 Jun;21(6):507–510. doi: 10.1016/0028-3908(82)90040-5. [DOI] [PubMed] [Google Scholar]
  27. Heal D. J., Philpot J., O'Shaughnessy K. M., Davies C. L. The influence of central noradrenergic function on 5-HT2-mediated head-twitch responses in mice: possible implications for the actions of antidepressant drugs. Psychopharmacology (Berl) 1986;89(4):414–420. doi: 10.1007/BF02412113. [DOI] [PubMed] [Google Scholar]
  28. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res. 1988;8(1-4):59–81. doi: 10.3109/10799898809048978. [DOI] [PubMed] [Google Scholar]
  29. Kennett G. A., Curzon G. Potencies of antagonists indicate that 5-HT1C receptors mediate 1-3(chlorophenyl)piperazine-induced hypophagia. Br J Pharmacol. 1991 Aug;103(4):2016–2020. doi: 10.1111/j.1476-5381.1991.tb12369.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  31. Leysen J. E., Gommeren W., Van Gompel P., Wynants J., Janssen P. F., Laduron P. M. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol. 1985 Jun;27(6):600–611. [PubMed] [Google Scholar]
  32. Limberger N., Bonanno G., Späth L., Starke K. Autoreceptors and alpha 2-adrenoceptors at the serotonergic axons of rabbit brain cortex. Naunyn Schmiedebergs Arch Pharmacol. 1986 Apr;332(4):324–331. doi: 10.1007/BF00500082. [DOI] [PubMed] [Google Scholar]
  33. Middlemiss D. N., Fozard J. R. 8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol. 1983 May 20;90(1):151–153. doi: 10.1016/0014-2999(83)90230-3. [DOI] [PubMed] [Google Scholar]
  34. Moser P. C., Tricklebank M. D., Middlemiss D. N., Mir A. K., Hibert M. F., Fozard J. R. Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol. 1990 Feb;99(2):343–349. doi: 10.1111/j.1476-5381.1990.tb14706.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Nimgaonkar V. L., Green A. R., Cowen P. J., Heal D. J., Grahame-Smith D. G., Deakin J. F. Studies on the mechanisms by which clenbuterol, a beta-adrenoceptor agonist, enhances 5-HT-mediated behaviour and increases metabolism of 5-HT in the brain of the rat. Neuropharmacology. 1983 Jun;22(6):739–749. doi: 10.1016/0028-3908(83)90098-9. [DOI] [PubMed] [Google Scholar]
  36. Rimele T. J., Henry D. E., Lee D. K., Geiger G., Heaslip R. J., Grimes D. Tissue-dependent alpha adrenoceptor activity of buspirone and related compounds. J Pharmacol Exp Ther. 1987 Jun;241(3):771–778. [PubMed] [Google Scholar]
  37. Schechter L. E., Bolaños F. J., Gozlan H., Lanfumey L., Haj-Dahmane S., Laporte A. M., Fattaccini C. M., Hamon M. Alterations of central serotoninergic and dopaminergic neurotransmission in rats chronically treated with ipsapirone: biochemical and electrophysiological studies. J Pharmacol Exp Ther. 1990 Dec;255(3):1335–1347. [PubMed] [Google Scholar]
  38. Schweizer E. E., Amsterdam J., Rickels K., Kaplan M., Droba M. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull. 1986;22(1):183–185. [PubMed] [Google Scholar]
  39. Svensson T. H., Bunney B. S., Aghajanian G. K. Inhibition of both noradrenergic and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine. Brain Res. 1975 Jul 11;92(2):291–306. doi: 10.1016/0006-8993(75)90276-0. [DOI] [PubMed] [Google Scholar]
  40. Yocca F. D., Wright R. N., Margraf R. R., Eison A. S. 8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats. Pharmacol Biochem Behav. 1990 Jan;35(1):251–254. doi: 10.1016/0091-3057(90)90234-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES